FindTrial
Sign In

Association of Systemic Inflammatory Biomarkers with Metabolic Dysfunction-Associated Fatty Liver Disease Complicated with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Association of Systemic Inflammatory Biomarkers with Metabolic Dysfunction-Associated Fatty Liver Disease Complicated with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126987
Enrollment
Unknown
Registered
2026-06-22
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Dysfunction-Associated Fatty Liver Disease

Interventions

Group of fatty liver disease related to metabolic dysfunction The group of fatty liver disease related to metabolic dysfunction complicated with type 2 diabetes:None

Sponsors

The Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >=18 years old, meeting the diagnosis of MASLD and T2DM.

Exclusion criteria

Exclusion criteria: 1. Patients with severe diseases of vital systems including heart, brain, lung, kidney, nerve and hematopoietic system; 2. Patients with severe mental illness; 3. Pregnant women, patients with malignant tumors and infectious diseases; 4. And patients with incomplete data.

Design outcomes

Primary

MeasureTime frame
Correlation between systemic inflammatory biomarkers and metabolic dysfunction-associated fatty liver disease with type 2 diabetes (core indices: SII index, SIRI index);Risk of MASLD with type 2 diabetes mellitus;—

Countries

China

Contacts

Public ContactPan Xiaoqiong

The Second Affiliated Hospital of Wenzhou Medical University

pxqiong@163.com+86 577 88002885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026